Beyond COVID-19 products, Pfizer is leveraging its oncology portfolio (including Padcev sales up 38% to $542 million) and a robust early-stage pipeline. CEO Albert Bourla highlighted upcoming readouts from potential growth drivers through 2030, with late-stage candidates in immunology and rare diseases. The firm is also preparing for generic competition in key franchises, emphasizing R&D investment and strategic collaborations to sustain future revenue and EPS momentum. The company’s 2025 guidance already incorporates existing tariffs from China, Canada and Mexico, and potential U.S. tariffs of up to 250% on imported pharmaceuticals. To offset margin pressures, Pfizer is executing a comprehensive cost-realignment program targeting $7.7 billion in gross savings (approximately $7.2 billion net) by 2027, including $4.5 billion by end-2025, $500 million in R&D reorganization savings by end-2026, and $1.5 billion from manufacturing optimization by end-2027. Pfizer reported second-quarter revenues of $14.7 billion, a 10% year-over-year increase, driven by strong sales of the Vyndaqel family (up 21% operationally to $1.62 billion), Comirnaty (up 95% to $381 million) and Paxlovid (up 71% to $427 million). Adjusted diluted EPS came in at $0.78, beating consensus by $0.20, and the company raised its full-year 2025 adjusted EPS guidance by $0.10 to a midpoint of $3.00 while maintaining its revenue outlook of $61 billion to $64 billion. Pfizer’s annual dividend of $1.71 per share reflects a modest increase from $1.52 in 2020 and $1.12 in 2015, yielding approximately 7.4% at current levels. With expiring patents on blockbusters such as Eliquis, Prevnar and Ibrance, and declining COVID-19 vaccine and Paxlovid sales, dividend growth faces headwinds. Investors are urged to monitor buybacks and other capital return programs alongside EPS trends when assessing shareholder returns.
Beyond COVID-19 products, Pfizer is leveraging its oncology portfolio (including Padcev sales up 38% to $542 million) and a robust early-stage pipeline. CEO Albert Bourla highlighted upcoming readouts from potential growth drivers through 2030, with late-stage candidates in immunology and rare diseases. The firm is also preparing for generic competition in key franchises, emphasizing R&D investment and strategic collaborations to sustain future revenue and EPS momentum. The company’s 2025 guidance already incorporates existing tariffs from China, Canada and Mexico, and potential U.S. tariffs of up to 250% on imported pharmaceuticals. To offset margin pressures, Pfizer is executing a comprehensive cost-realignment program targeting $7.7 billion in gross savings (approximately $7.2 billion net) by 2027, including $4.5 billion by end-2025, $500 million in R&D reorganization savings by end-2026, and $1.5 billion from manufacturing optimization by end-2027. Pfizer reported second-quarter revenues of $14.7 billion, a 10% year-over-year increase, driven by strong sales of the Vyndaqel family (up 21% operationally to $1.62 billion), Comirnaty (up 95% to $381 million) and Paxlovid (up 71% to $427 million). Adjusted diluted EPS came in at $0.78, beating consensus by $0.20, and the company raised its full-year 2025 adjusted EPS guidance by $0.10 to a midpoint of $3.00 while maintaining its revenue outlook of $61 billion to $64 billion. Pfizer’s annual dividend of $1.71 per share reflects a modest increase from $1.52 in 2020 and $1.12 in 2015, yielding approximately 7.4% at current levels. With expiring patents on blockbusters such as Eliquis, Prevnar and Ibrance, and declining COVID-19 vaccine and Paxlovid sales, dividend growth faces headwinds. Investors are urged to monitor buybacks and other capital return programs alongside EPS trends when assessing shareholder returns.